Definition:Proof of funds letter
💵 Proof of funds letter is a document provided by a prospective buyer — or its financing source — to demonstrate that the financial resources necessary to complete an acquisition are available and committed. In insurance M&A, where regulatory approvals hinge on the acquirer's financial strength and ability to maintain the target's solvency capital post-closing, a credible proof of funds letter serves double duty: it satisfies the seller that the buyer can close, and it supports the regulatory submission to insurance supervisors who must approve the change of control.
🏛️ The letter typically originates from a bank, private equity fund, or the buyer's treasury function and confirms either that liquid funds are on deposit or that a committed financing facility is in place. For sponsor-backed insurance deals, it may take the form of an equity commitment letter from the fund, often accompanied by a debt commitment letter from lending banks if leverage is part of the capital structure. Insurance regulators — from the NAIC-coordinated state review process in the US, to the PRA in the UK, to the CBIRC in China — routinely require evidence of funding adequacy as part of their Form A or equivalent change-of-control filings. A conditional or heavily caveated letter will draw immediate skepticism from both seller and regulator.
🔑 Timing and specificity matter enormously. Sellers conducting a competitive auction often require proof of funds alongside binding bids, using the quality of the letter as a differentiator between otherwise comparable offers. A buyer that can demonstrate unconditional, fully committed funding gains a material advantage over a rival whose financing remains subject to additional approvals or market conditions. In practice, the proof of funds letter also interacts with the process letter requirements and SPA conditionality: a buyer with confirmed funds can offer fewer conditions precedent, which makes its bid more attractive to sellers seeking deal certainty — a particularly prized attribute in insurance transactions where the path to regulatory approval can already introduce months of uncertainty.
Related concepts: